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Ehrlich ascites carcinoma is a spontaneous murine mammary adenocarcinoma adapted to ascites form and carried in outbred
mice by serial intraperitoneal (i/p) passages. The previous work from our laboratory showed that honey having higher phenolic
content was potent in inhibiting colon cancer cell proliferation. In this work, we extended our research to screen the antitumor
activity of two selected honey samples and eugenol (one of the phenolic constituents of honey) against murine Ehrlich ascites and
solid carcinoma models. Honey containing higher phenolic content was found to significantly inhibit the growth of Ehrlich ascites
carcinoma as compared to other samples. When honey containing higher phenolic content was given at 25% (volume/volume)
intraperitoneally (i/p), the maximum tumor growth inhibition was found to be 39.98%. However, honey was found to be less
potent in inhibiting the growth of Ehrlich solid carcinoma. On the other hand, eugenol at a dose of 100mg/kg i/p was able to
inhibit the growth of Ehrlich ascites by 28.88%. In case of solid carcinoma, eugenol (100mg/kg; i/p) showed 24.35% tumor growth
inhibition. This work will promote the development of honey and eugenol as promising candidates in cancer chemoprevention.
1. Introduction
The previous work from our laboratory showed that honey
could induce apoptosis in colon cancer cell lines. In the
present studies, four honey samples named as Sample A,
B, C, and D of different origins were investigated for their
phenolic content. Among them, Sample C showed higher
phenolic content of 65.06 Gallic acid equivalent (GAE), per
100 g of honey followed by Sample A (60 GAE), Sample
D (47.10 GAE) and Sample B (29.96 GAE). The apoptotic
potential of honey against colon cancer cells was found
to vary among the samples depending upon the phenolic
content. Sample C showing higher phenolic content was
found to be more potent in inhibiting the cancer cell
proliferation as compared to other samples [1, 2]. In this
work, we investigated the antitumor effect of two honey
samples (Sample C possessing higher phenolic content and
Sample B with lower phenolic content) as well as eugenol
(one of the phenolic constituents of honey) against Ehrlich
ascites and solid carcinoma.
Ehrlich ascites carcinoma is a spontaneous murine
mammary adenocarcinoma [3] adapted to ascites form
and carried in outbred mice by serial intraperitoneal (i/p)
passages. It has been reported that Ehrlich ascites tumor cells
lack H-2 histocompatibility antigens [4], which apparently
is the reason for their rapid proliferation in almost any
mouse host [5]. Since the description of Ehrlich ascites,
researchers exploit it for chemotherapeutic studies. In one
recent study, Bhattacharyya et al. [6] studied the apoptogenic
effect of black tea against Ehrlich ascites [6]. Moreover effect
of antioxidants in development of ascites carcinoma [7]
and the role of jacalin in inhibiting the in vivo growth of
Ehrlich ascites were also studied [8]. There are various ways
to evaluate the antitumor efficacy of any compound against
Ehrlich ascites. To mention: (1) examine the ascites cells
cytologically after treatment, (2) to measure the increase in
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survival time after using the desired compound of study, and
(3) to measure the amount of ascites formed after therapy.
For our studies we have used the last mentioned method to
evaluate the efficacy of honey samples and eugenol.
Several researchers have investigated the effect of crude
honey on cancer. Research conducted on the antitumor
activity of honey showed that it possesses moderate anti-
tumor and significant antimetastatic effects in five different
kinds of rat and mouse tumors. Moreover, the antitumor
activity of certain chemotherapeutic drugs such as 5-
fluorouracil and cyclophosphamide was facilitated by honey
[9]. In vivo studies conducted by Swellam et al. [10]
reported that intralesional injection of 6 and 12% honey
as well as oral ingestion of honey significantly inhibited
the tumor growth [10]. Eugenol showed significant tumor
growth delay, by decreasing the tumor size and inhibiting the
tumor metastasis in B16F10 xenograft study [11]. In another
research, tumors (papillomas) produced by the application
of 7,12-dimethyl benz (a) anthracene as initiator and croton
oil as promoter in mice were considerably inhibited by the
prior application of eugenol [12].
This work reports the results of antitumor effects of the
selected honey samples and eugenol against Ehrlich ascites
and solid carcinoma. This work will determine whether the
amount of phenolic constituent will have any effect on the
antitumor activity of honey against Ehrlich ascites and solid
carcinomas.
2. Materials and Methods
2.1. Ehrlich Ascites Carcinoma. Ehrlich ascites carcinoma
(EAC) cells were collected from the ascitic fluid of BALB/c
mice harbouring 8–10 days old ascitic tumor. 1 × 107 EAC
cells were injected intraperitoneally in 52 BALB/c female
mice selected for the experiment on day 0. The next day,
animals were randomized and divided into seven groups. Six
treatment groups contained 7 animals each and one control
group contained 10 animals. Treatment was given as follows:
Group I: Control (0.2mL of saline; i/p) from day 1
to 9,
Group II: 0.2mL of 25% (v/v) solution of Sample B
in normal saline injected consecutively from day 1
to 9 (i/p),
Group III: 0.2mL of 25% (v/v) solution of Sample
C in normal saline injected consecutively from day 1
to 9 (i/p),
Group IV: Eugenol (80mg/Kg; i/p) injected consecu-
tively from day 1 to 9,
Group V: Eugenol (100mg/Kg; i/p) injected consecu-
tively from day 1 to 9,
Group VI: Eugenol (125mg/Kg; i/p) injected consec-
utively from day 1 to 9,
Group VII: 5-Flurouracil (20mg/Kg; i/p) injected
consecutively from day 1 to 9.
The first group administered normal saline (0.2mL, i/p)
from day 1 to 9 was the tumor bearing control; whereas
seventh group treated with 5-fluorouracil served as positive
control. On day 12, animals were sacrificed and ascitic
fluid was collected from peritoneal cavity of each mouse
for the evaluation of tumor growth. Percent tumor growth
inhibition was calculated by comparing the total number of
tumor cells present in the peritoneal cavity of treated groups
and the control group as on day 12 of the experiment. Tumor
cell growth in saline-treated control group was taken as 100
percent cell growth.
2.1.1. Preparation and Administration of Doses. For honey
samples, 25% (volume/volume) solutions were prepared in
normal saline and 0.2mL of these solutions was administered
to each mouse intraperitoneally every day at 2.00 PM from
days 1 to 9. For Eugenol, its dose (in mg) was divided by
its specific gravity (1.06) to arrive at its volume to be used
in dose preparation. The required volume was emulsified
in distilled water by using Tween 80 (0.5% of the total
volume). The emulsion was prepared in such a way that the
required daily dose was contained in 0.2mL of the emulsion.
0.2mL of this emulsion was administered to each mouse
intraperitoneally, daily at 2.00 PM from day 1 to 9.
2.2. Ehrlich Tumor (Solid). Ehrlich ascites carcinoma (EAC)
cells were collected from the ascitic fluid of BALB/c mice
harbouring 8–10 days old ascitic tumor. 1 × 107 EAC cells
were injected intramuscularly in right thigh of 38 BALB/c
male mice selected for the experiment on day 0. The next
day, animals were randomized and divided into four groups.
Three treatment groups contained 7 animals each and one
control group contained 10 animals. Treatment was given as
follows:
Group I: Control (normal saline (0.2mL, i/p) inject-
ed consecutively from day 1 to 9),
Group II: 0.2mL of 50% (v/v) solution of Sample C
in normal saline injected consecutively from day 1 to
9 (i/p),
Group III: Eugenol (100mg/Kg; i/p) injected consec-
utively from day 1 to 9,
Group IV: 5-Flurouracil (20mg/Kg; i/p) injected
consecutively from day 1 to 9.
The first group administered normal saline (NS) (0.2mL,
i/p) was the tumor bearing control and the fourth group
treated with 5-fluorouracil served as positive control. On
days 9 and 13, tumor bearing thigh of each animal was
shaved and longest and shortest diameters of the tumor were
measured with the help of vernier caliper. Tumor weight of
each animal was calculated using the following formula:
Tumor weight
(
mg
) = Length(mm)× {width(mm)}
2
2
.
(1)
The percent tumor growth inhibition was calculated on day
13 by comparing the average values of treated groups with
that of tumor bearing control group. Tumor growth in saline
treated control animals was taken to be 100%.
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Table 1: Body Weights of the Animal after the Treatment.
Treatment Dose
Body weight (g)
Day 1 Day 5 Day 9 Day 12
Control 0.2 mL NS i/p 22.75 25.37 25.62 27.00
Sample B 25% (v/v) i/p 22.71 24.57 24.57 27.28
Sample C 25% (v/v) i/p 22.85 24.66 24.83 25.33
Eugenol 80 mg/kg i/p 22.71 23.28 24.66 25.91
Eugenol 100 mg/kg i/p 22.85 23.82 24.28 25.33
Eugenol 125 mg/kg i/p 22.57 19.00 19.66 Animals died
5-FU 20 mg/kg i/p 23.00 22.57 21.85 20.42
2.2.1. Preparation and Administration of Doses. For honey
sample, 50% (volume/volume) solution was prepared in
normal saline and 0.2mL of this solution was administered
to each mouse intraperitoneally daily at 2.00 PM from days 1
to 9. For Eugenol, its dose (in mg) was divided by its specific
gravity (1.06) to arrive at its volume to be used in dose
preparation. The required volume was emulsified in distilled
water by using Twin 80 (0.5% of the total volume). The
emulsion was prepared in such a way that the required daily
dose was contained in 0.2mL of the emulsion. 0.2mL of this
emulsion was administered to each mouse intraperitoneally,
daily at 2.00 PM from day 1 to 9.
3. Results
3.1. Ehrlich Ascites Carcinoma. Body weights of animals were
measured regularly on predetermined days. The body weight
at the end of day 12 was more compared to the day 1 in all
the experimental animals except in case of 5-FU treatment
where it showed a decrease. Moreover 125mg/kg of eugenol
dose was found to be toxic to animals. While comparing
the body weight of saline control on day 12 with Sample C
and Eugenol treated animals, a decrease in body weights was
observed indicating these samples to have effect on the body
weights of treated animals (Table 1).
Further more, average volume of ascitic fluid was
measured by scarifying all the animals at the end of day
12. Volume collected from the Sample C treated animals
(3.41mL) was found to be less compared to other treatment
groups. The number of tumor cells present in the ascitic
fluid of each treatment group was also counted. It was
observed that Sample C treated animals had only 56.70×107
tumor cells as compared to 94.47 × 107 cells in the saline
treated control group. Finally, the percent tumor growth
inhibition was calculated and it was found to be 12.17 and
39.98% for Sample B and Sample C, respectively. For eugenol
it was observed to be 20.56% (80mg/kg i/p) and 28.88%
(100mg/kg i/p). Eugenol dose of 125 mg/kg was found to be
toxic to the animals (Table 2).
3.2. Ehrlich Tumor (Solid). Similar to ascites model, the body
weights of animals were measured on predetermined days.
The body weights taken on day 12 did not show any decrease
in any of the experimental groups as compared to day 1
weights. However, day 12 body weights of animals treated
Sample C and Eugenol were quite lesser as compared to saline
treated control indicating these samples to have an effect
on the body weights. Further more, average tumor weights
calculated on day 12 were found to be considerably less in
Eugenol (1412.64mg) and Sample C (1786.14mg) treated
groups as compared to 1867.35 mg in saline-treated control.
The growth inhibition of Ehrlich tumor (solid) was found
to be 24.35 and 4.34% for Eugenol and Sample C treated
animals, respectively (Table 3).
4. Discussion
Epidemiological surveys and experimental studies have pro-
vided evidence that environmental factors, including dietary
substances, play a major role in the incidence of cancer.
Our previous studies reported that the apoptotic potential of
honey varied according to the source and phenolic content
[1, 2]. Further more, the molecular mechanism behind the
apoptotic potential of honey in vitro was clearly elucidated
[13]. Since the apoptotic potential of honey was ascribed
to its phenolic constituents, apoptosis inducing mechanism
of eugenol, one of the phenolic constituents of honey, was
also studied in colon cancer cell lines (unpublished data).
In the present studies, we investigated the in vivo effect
of honey and eugenol against murine Ehrlich ascites and
solid carcinoma models as a preliminary study to initiate
our work against immunosuppressive colon cancer in mice
models. The choice of honey was made from our previous
studies which showed Samples C and B possessing higher
and lower phenolic content, respectively. This choice was
made to ascertain whether phenolic content has a role
in the anticancer activity against Ehrlich ascites and solid
carcinoma.
We used 25% v/v honey solution against Ehrlich ascites
carcinoma model. This concentration was chosen arbitrarily
and also to overcome the highly viscous nature of honey.
Results showed that honey having higher phenolic content
(Sample C) inhibited the growth of Ehrlich ascites more
effectively as compared to other sample (Sample B). These
findings corroborate well with our earlier results obtained
in in vitro apoptosis studies conducted on the colon cancer
cells where it was observed that the honey containing
higher phenolic content was able to inhibit the cancer cell
proliferation remarkably as compared to other samples [1].
Mitochondrial and ROS-mediated apoptotic mechanisms
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Table 2: Percentage of Tumor Inhibition of Ehrlich Ascites after Treatment.
Treatment Dose
Day 12
Avg. volume of
ascitic fluid
(mL)
Avg. weight of
ascitic fluid (g)
Avg. No. of
tumor cells
×107
% Tumor cell
growth
% Tumor
growth
inhibition
Mortality
Control 0.2mL NS i/p 7.64 8.16 94.47 100.00 00.00 0/10
Sample B 25% (v/v) i/p 7.01 7.33 82.97 87.83 12.17 0/7
Sample C 25% (v/v) i/p 3.41 3.66 56.70 60.02 39.98 0/7
Eugenol 80mg/kg i/p 7.02 7.46 84.09 79.44 20.56 0/7
Eugenol 100mg/kg i/p 9.88 9.86 75.28 71.12 28.88 0/7
Eugenol 125mg/kg i/p All animals died by 10th day Intolerable 7/7
5-FU 20mg/Kg i/p 0.40 0.38 05.23 05.54 94.46 0/7
Table 3: Average Weights and Tumor Inhibition of Ehrlich Solid Tumor after Treatment.
Treatment
Groups
Avg. Body weights (g) of animals on days Day 13 %Tumor
growth
inhibition
Mortality
1 5 9
Avg. body
weights (g)
Avg. tumor weights
(mg)
Eugenol
(100mg/kg i/p)
19.57 21.0 19.71 20.57 1412.64 24.35 0/7
Sample C (50%
v/v i/p)
19.85 20.71 20.71 21.57 1786.14 4.34 0/7
Positive control
5 FU (22mg/kg
i/p)
21.14 21.71 21.16 21.33 1275.5 31.69 0/7
Normal Control
NS (0.2mL i/p)
21.25 22.71 22.42 22.71 1867.35 — 0/10
observed in the antiproliferative activity of honey might
have a putative role in the antitumor activity of honey
against Ehrlich ascites [13]. The antitumor effect of honey
observed in the present investigation was similar to the
effect of some other natural products like black tea and
jacalin against Ehrlich ascites reported previously [6, 8].
Ehrlich solid carcinoma bearing animals were treated with
increased concentration of honey (50% v/v) since these
animals were found to be more resistant to treatment
with honey as compared to ascites bearing animals. Results
demonstrated that even at such a higher concentration of
honey, it could not show any drastic change in the growth
of Ehrlich solid carcinoma. The antitumor efficacy against
solid carcinoma was only 4.34% compared to 39.98% against
ascites carcinoma. This inefficacy of honey may be due to the
systemic effect necessitated by the solid carcinoma.
In case of Eugenol, we had chosen three arbitrary
concentrations of 80, 100, and 125mg/kg based on the recent
anticancer work done against melanoma [11]. In our studies,
a dose of 125mg/kg proved toxic to animals. A dose of
100mg/kg was found to be potent against Ehrlich ascites with
an antitumor efficacy of 29% approximately. Hence we used
the same concentration (100mg/kg) against Ehrlich solid
tumor. Although efficacy against Ehrlich solid tumor was less
for honey, eugenol showed a fairly good inhibition in the
growth of solid tumor (antitumor efficacy of 24.35%). The
observed antitumor effect was analogous with the previous
report on its antitumor activity against B16F10 xenograft
study [11] and in tumors (papillomas) produced by the
application of 7, 12-dimethyl benz (a) anthracene as initiator
[12].
Our studies confirmed that the honey with higher
phenolic content inhibits the growth of Ehrlich ascites more
effectively. Hence antitumor effect against Ehrlich ascites
could be attributed to its phenolic content and its antioxidant
ability, since Sample C showed significant effect as compared
to Sample B. In case of solid Ehrlich tumor honey was found
to be less potent. This may occur because of more resistant
nature of Ehrlich tumor (solid) and its inhibition requiring
systemic effect. Eugenol had shown remarkable inhibition
of both Ehrlich ascites and solid tumor. We surmise that
mitochondrial and ROS-mediated apoptotic mechanism
observed in the antiproliferative activity of honey might have
a role in this antitumor activity [13]. To explain further, it
is essential to study the exact molecular mechanism behind
the antitumor activity of honey and eugenol against Ehrlich
tumor.
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